A novel combined ex vivo and in vivo lentiviral interleukin-10 gene delivery strategy at the time of transplantation decreases chronic lung allograft rejection in mice

被引:22
作者
Oishi, Hisashi [1 ]
Juvet, Stephen C. [1 ]
Martinu, Tereza [1 ]
Sato, Masaaki [1 ,2 ]
Medin, Jeffrey A. [3 ,4 ]
Liu, Mingyao [1 ]
Keshavjee, Shaf [1 ]
机构
[1] Univ Toronto, Univ Hlth Network, Latner Thorac Surg Res Labs, Toronto, ON, Canada
[2] Univ Tokyo, Dept Thorac Surg, Tokyo, Japan
[3] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA
基金
加拿大健康研究院;
关键词
lung transplantation; interleukin-10; lentivirus; acute rejection; chronic rejection; REGULATORY T-CELLS; GRAFT FUNCTION; RAT LUNG; IL-10; THERAPY; AIRWAY; MODEL; OBLITERATION; INFLAMMATION; EXPRESSION;
D O I
10.1016/j.jtcvs.2018.05.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Our objective was to develop a rapid-onset and durable gene-delivery strategy that is applicable at the time of transplant to determine its effects on both acute rejection and chronic lung allograft fibrosis using a mouse orthotopic lung transplant model. Methods: C57BL/6 mice received an orthotopic left lung transplant from syngeneic donors or C57BL/10 donors. By using syngeneic lung transplantation, we established a novel gene transfer protocol with lentivirus luciferase intrabronchial administration to the donor lung ex vivo before transplantation. This strategy was applied in allogeneic lung transplantation with lentivirus engineering expression of human interleukin-10 or lentivirus luciferase (control). Results: Bioluminescent imaging revealed that the highest early transgene expression was achieved when lentivirus luciferase was administered both directly into the donor lung graft ex vivo before implantation and subsequently to the recipient in vivo daily on post-transplant days 1 to 4, compared with post-transplant in vivo administration only (days 0 to 4). Our previous work with adenoviral interleukin-10 gene therapy indicates that early interleukin-10 expression in the allograft is desirable. Therefore, we selected the combined protocol for human interleukin-10 encoding lentiviral vector therapy. In the allogeneic transplant setting, ex vivo and in vivo human interleukin-10 encoding lentiviral vector therapy reduced acute rejection grade (2.0 vs 3.0, P < .05) at day 28. The percentage of fibrotic obliterated airways was reduced in the human interleukin-10 encoding lentiviral vector-treated group (10.9% +/- 7.7% vs 40.9% +/- 9.3%, P < .05). Conclusions: Delivery of lentiviral interleukin-10 gene therapy, using a novel combined ex vivo and in vivo delivery strategy, significantly improves acute and chronic rejection in the mouse lung transplant model.
引用
收藏
页码:1305 / 1315
页数:11
相关论文
共 30 条
[1]   Cutting edge:: The mouse NK cell-associated antigen recognized by DX5 moncoclonal antibody is CD49b (α2 integrin, very late antigen-2) [J].
Arase, H ;
Saito, T ;
Phillips, JH ;
Lanier, LL .
JOURNAL OF IMMUNOLOGY, 2001, 167 (03) :1141-1144
[2]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[3]   Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-β induction of transcription factor Foxp3 [J].
Chen, WJ ;
Jin, WW ;
Hardegen, N ;
Lei, KJ ;
Li, L ;
Marinos, N ;
McGrady, G ;
Wahl, SM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2003, 198 (12) :1875-1886
[4]   Functional Repair of Human Donor Lungs by IL-10 Gene Therapy [J].
Cypel, Marcelo ;
Liu, Mingyao ;
Rubacha, Matt ;
Yeung, Jonathan C. ;
Hirayama, Shin ;
Anraku, Masaki ;
Sato, Masaaki ;
Medin, Jeffrey ;
Davidson, Beverly L. ;
de Perrot, Marc ;
Waddell, Thomas K. ;
Slutsky, Arthur S. ;
Keshavjee, Shaf .
SCIENCE TRANSLATIONAL MEDICINE, 2009, 1 (04)
[5]  
Das NA, 2017, J THORAC CARDIOVASC, V154
[6]   Impact of human interleukin-10 on vector-induced inflammation and early graft function in rat lung transplantation [J].
de Perrot, M ;
Fischer, S ;
Liu, MY ;
Imai, Y ;
Martins, S ;
Sakiyama, S ;
Tabata, T ;
Bai, XH ;
Waddell, TK ;
Davidson, BL ;
Keshavjee, S .
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2003, 28 (05) :616-625
[7]   Interleukin 10 gene transfection of donor lungs ameliorates posttransplant cell death by a switch from cellular necrosis to apoptosis [J].
Fischer, S ;
de Perrot, M ;
Liu, MY ;
MacLean, AA ;
Cardella, JA ;
Imai, Y ;
Suga, M ;
Keshavjee, S .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2003, 126 (04) :1174-1180
[8]   In vivo transtracheal adenovirus-mediated transfer of human interleukin-10 gene to donor lungs ameliorates ischemia-reperfusion injury and improves early posttransplant graft function in the rat [J].
Fischer, S ;
Liu, MY ;
MacLean, AA ;
de Perrot, M ;
Ho, M ;
Cardella, JA ;
Zhang, XM ;
Bai, XH ;
Suga, M ;
Imai, Y ;
Keshavjee, S .
HUMAN GENE THERAPY, 2001, 12 (12) :1513-1526
[9]   Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease [J].
Griesenbach, Uta ;
Alton, Eric W. F. W. .
CURRENT PHARMACEUTICAL DESIGN, 2012, 18 (05) :642-662
[10]   A CD4(+) T-cell subset inhibits antigen-specific T-cell responses and prevents colitis [J].
Groux, H ;
OGarra, A ;
Bigler, M ;
Rouleau, M ;
Antonenko, S ;
deVries, JE ;
Roncarolo, MG .
NATURE, 1997, 389 (6652) :737-742